SLNO vs. RYTM, LRMR, FONR, RMTI, TMDX, ITGR, LIVN, CNMD, INMD, and BLFS
Should you be buying Soleno Therapeutics stock or one of its competitors? The main competitors of Soleno Therapeutics include Rhythm Pharmaceuticals (RYTM), Larimar Therapeutics (LRMR), FONAR (FONR), Rockwell Medical (RMTI), TransMedics Group (TMDX), Integer (ITGR), LivaNova (LIVN), CONMED (CNMD), InMode (INMD), and BioLife Solutions (BLFS). These companies are all part of the "medical" sector.
Soleno Therapeutics (NASDAQ:SLNO) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, community ranking, profitability, dividends and earnings.
Soleno Therapeutics presently has a consensus price target of $60.33, suggesting a potential upside of 43.38%. Rhythm Pharmaceuticals has a consensus price target of $54.33, suggesting a potential upside of 52.28%. Given Rhythm Pharmaceuticals' higher possible upside, analysts clearly believe Rhythm Pharmaceuticals is more favorable than Soleno Therapeutics.
Soleno Therapeutics has higher earnings, but lower revenue than Rhythm Pharmaceuticals. Soleno Therapeutics is trading at a lower price-to-earnings ratio than Rhythm Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Soleno Therapeutics has a beta of -1.51, suggesting that its stock price is 251% less volatile than the S&P 500. Comparatively, Rhythm Pharmaceuticals has a beta of 1.94, suggesting that its stock price is 94% more volatile than the S&P 500.
Soleno Therapeutics has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -297.91%. Soleno Therapeutics' return on equity of -61.84% beat Rhythm Pharmaceuticals' return on equity.
Soleno Therapeutics received 24 more outperform votes than Rhythm Pharmaceuticals when rated by MarketBeat users. Likewise, 71.43% of users gave Soleno Therapeutics an outperform vote while only 65.71% of users gave Rhythm Pharmaceuticals an outperform vote.
In the previous week, Rhythm Pharmaceuticals had 2 more articles in the media than Soleno Therapeutics. MarketBeat recorded 5 mentions for Rhythm Pharmaceuticals and 3 mentions for Soleno Therapeutics. Soleno Therapeutics' average media sentiment score of 1.20 beat Rhythm Pharmaceuticals' score of 0.59 indicating that Soleno Therapeutics is being referred to more favorably in the media.
97.4% of Soleno Therapeutics shares are owned by institutional investors. 12.3% of Soleno Therapeutics shares are owned by insiders. Comparatively, 5.6% of Rhythm Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Soleno Therapeutics beats Rhythm Pharmaceuticals on 13 of the 18 factors compared between the two stocks.
Get Soleno Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SLNO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SLNO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Soleno Therapeutics Competitors List
Related Companies and Tools
